Last reviewed · How we verify
Prevention of COVID-19 in individuals 6 months through 11 years of age — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose | variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose | Pfizer | mRNA vaccine | SARS-CoV-2 spike protein |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Prevention of COVID-19 in individuals 6 months through 11 years of age
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of COVID-19 in individuals 6 months through 11 years of age:
- Prevention of COVID-19 in individuals 6 months through 11 years of age treatment updates — RSS
- Prevention of COVID-19 in individuals 6 months through 11 years of age treatment updates — Atom
- Prevention of COVID-19 in individuals 6 months through 11 years of age treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of COVID-19 in individuals 6 months through 11 years of age — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-covid-19-in-individuals-6-months-through-11-years-of-age. Accessed 2026-06-10.
Related
- Prevention of COVID-19 in individuals 6 months through 11 years of age full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing